where R^{3a} is F; and

(5)



where

R^x is OCH_3 and R^{3b} is OCH_3 or

R^x is CH_3 and R^{3b} is Cl.

12. The compound as defined in Claim 1, wherein the compound is selected from one of the examples.

13. A pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a compound as defined in Claim 1, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, alone or in combination with another therapeutic agent.

14. ~~A method for the treatment of a thromboembolic disorder or the primary or secondary prophylaxis of a thromboembolic disorder, which comprises the steps of administering to a patient in need thereof~~ Use of a therapeutically effective amount of a compound as defined in Claim 1, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof in the manufacture of a medicament for the treatment of a thromboembolic disorder or the primary or secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, cerebrovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation.

15. ~~A method of inhibiting or preventing platelet aggregation, which comprises the step of administering to a subject in need thereof~~ Use of a therapeutically effective amount of a PAR4 antagonist, as defined in Claim 1, in the manufacture of a medicament for inhibiting or preventing platelet aggregation.